Nephrotic Syndrome With Positive Anti-PLA2R: Biopsy or Empirical Therapy?
A 34-year-old man presents with 3 weeks of bilateral leg edema and foamy urine. BP 142/88 mmHg, BMI 31 kg/m². Urine protein-to-creatinine ratio 5.1 g/g, serum albumin 2.2 g/dL, creatinine 1.0 mg/dL (baseline 0.9), glucose 92 mg/dL, hemoglobin 14.2 g/dL. Serologies: anti-PLA2R antibody 165 RU/mL, ANA negative, anti-dsDNA negative, hepatitis B surface antigen negative, hepatitis C antibody negative, HIV negative. Complement C3 and C4 normal. Kidney ultrasound shows normal-sized echogenic kidneys without obstruction. Urinalysis shows 3+ protein, no red cells, and no casts. He has no history of NSAID use, and his only medication is lisinopril 10 mg daily. He has no family history of kidney disease. The patient asks whether he can start treatment without a kidney biopsy and whether he needs blood thinners. The nephrologist must decide on the next step and address anticoagulation.
1. Should this patient undergo kidney biopsy before starting immunosuppression, or is serologic diagnosis sufficient? Justify your answer.
Read the worked answer
The decision hinges on the pretest probability of primary membranous nephropathy and on what the biopsy adds beyond serology. A PLA2R antibody of 165 RU/mL in a nephrotic patient with normal complement, negative secondary workup, and preserved eGFR has high specificity for primary membranous nephropathy. Some guidance allows empirical treatment without biopsy when serology is strongly positive and the clinical picture is typical. However, biopsy still confirms the diagnosis, stages the lesion, identifies superimposed disease, and provides a baseline if treatment fails. In a 34-year-old with new nephrotic syndrome, I would generally biopsy unless contraindicated, because early FSGS or IgA with heavy proteinuria can mimic this picture and because prognosis depends on chronicity. If the patient refuses, empirical rituximab or cyclophosphamide plus steroids is reasonable after consent, with repeat PLA2R at 3 and 6 months. Immunosuppression should not begin before excluding active infection and hepatitis.
2. What is the role of prophylactic anticoagulation in this patient? Include risk stratification.
Read the worked answer
Serum albumin 2.2 g/dL and proteinuria 5.1 g/g place him at moderate thrombotic risk, but routine prophylactic anticoagulation is not automatic. A common approach considers prophylaxis when albumin is below 2.5 g/dL plus at least one additional risk factor, such as proteinuria above 10 g/g, BMI above 35, prior venous thromboembolism, or a genetic thrombophilia. He has BMI 31 and proteinuria 5.1 g/g, so he meets only the albumin criterion. I would not start anticoagulation routinely. Reassess if albumin falls below 2.0 g/dL, proteinuria rises, or immobility develops. If anticoagulation is chosen, a direct oral anticoagulant is increasingly used, but warfarin remains an option; bleeding risk and shared decision-making matter. This is a judgment call, not a reflex.